8 natera" | ONCOLOGY

Please place Signatera/Altera sample kit barcode here 34567-2-X SB/ST

Date of Sample Collection (MM/DD/YY)*

Please send completed form in sample kit. For Natera-collected samples, email form to <u>oncologyCE@natera.com</u> or fax to +1 (650) 412-1962 (*) denotes required fields. Failure to complete will result in testing delays. | Inquiries: +1 (650) 489-9050

1. PATIENT INFORMATION*				2. ORDERING CLINICIA	4N*						
Last Name*	Middle Name*	First N	lame*	Ordering Clinician*			NPI N	NPI Number			
Date of Birth (MM/DD/YY)*	Sex Assigned at Birth *	MRN	Last 4 digits of SSN	N (Natera Account ID) Clinic or Organization*							
Email Address		Cell Phone *	Street Address* ()		City*	State*	Zip Code*				
Street Address*				Telephone Number *	Clinic or Organization Fax or Email *						
City*		State *	Zip Code*	Additional Report Recipient	Recipient Additional Report Recipient Fax or Email		I				

STATEMENT OF MEDICAL NECESSITY I confirm the testing ordered herein is medically necessary and this patient has been informed of the details of the genetic test(s) ordered, including the risks, benefits, and alternatives, and has consented to testing as may be required by law, including NY CVR §79-I, as applicable. I authorize the referral of this patient to a third-party genetic counseling service if required by the patient's insurance provider.

I hereby authorize the pathology laboratory to release the patient's specimen to Natera.

Ordering Clinician / Authorized Signature*

Date*

3. TEST ORDER SELECTION*							
SIGNATERA Molecular Residual Disease (MRD)	ALTERA Tissue Comprehensive Genom	ic Profiling (CGP)	EMPOWER Germline Hereditary	VER e Hereditary Cancer			
Must select only one testing cadence below: 4 weeks Please indicate the total number of desired draws: 8 weeks If left blank, order will default to 12 months of draws 6 months Single test order MRD & Recurrence Monitoring recommended cadence See back for cadence schedule & additional test details	 Whole Exome DNA (inclusive of MSI and TMB) + Whole Transcriptome RNA Sequencing Available for Active Stage III / IV / Recurrent only. If ordered with an initial Signatera test, Altera can be run using the same tissue and blood samples. If Signatera has been previously ordered for this patient, additional blood and tissue samples are required. Not available for samples collected in NY State. 		Must select only one base test below: OBRCA1 & BRCA2 OLynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Other Panel ID May select only one additional test (optional): Multi-Cancer (40 genes total) Comprehensive (81 genes total) Must complete "Empower Information" section on back AND collect Empower EDTA tube in Signatera/Altera blood kit.				
4. SIGNATERA & ALTERA CLINICAL INFORMATI		ICD-10 CODES*					
Cancer type to be tested for Signatera/Altera:* (select one cancer type) Enter relevant codes for each test							
O Colorectal O Bladder O Breast O Lung O Melanon Subtype Stage:* O I O II Is patient receiving or planning to receive immunotherapy? O Yes O No O Unknown □ please enter drug name(s)	III IV Other IV Other Iteration Iteration Iteration Iteration Ves No No			Signatera & Altera Empower For codes, visit: <u>natera.com/icd10codes</u>			
5. SPECIMEN COLLECTION & RETRIEVAL – Initial Order							

	nlebotomy (default) O C ult) OR O Clinic will coord	-	managed for first draw, Natera r e to Natera. Notes:	
O Most recent progress/clinical note attached* O Pathology report attached* Tissue acquisition cannot occur without a pathology report	Pathology Lab Name / Co	ontact*	Address	
Tissue Collection Date (MM/DD/YY)	City		State	Zip
Accession # / Block ID # Please see instructions in kit for details	Phone*	Fax*	Email	
6. INSURANCE & PAYMENT INFORMATION				
Please attach front and back of insurance card.	/ledicare only – Patient Sta	tus: O If inpatient, add	Date of Discharge	Outpatient
Bill To:* O Medicare O Self-pay O Other Insurance O Clinic Insurance Co	ompany*	Member ID*	Group Number	Prior Authorization Number
7. PATIENT ACKNOWLEDGMENT				
By my signature I acknowledge that I have read and agre New York residents must check this box and sign below to p I understand that my/my child's treatment, payment, enrollment	ermit Natera to use their samp	les for research and develo	• • •	

on my providing such consent, and I may opt out at any time or by checking this box .

I hereby authorize Natera, Inc. to obtain my/my child's pathology specimens.

Patient/Guardian Signature*

Date*

By providing the information included herein, I understand and agree I may be contacted by email, cell, home phone, text message, automatic telephone dialing system, or computer assisted technology for treatment options, billing/collection matters, and health-related products, services, or studies.

CONTRAINDICATIONS

Signatera testing: Patients with a history of allogenic bone marrow transplant, OR have had blood transfusions within the last three months Empower testing: Patients with a history of allogenic bone marrow transplant, OR have current or previous history of hematologic malignancy

BLOOD DRAW MANAGEMEN1

-	na	te	ra


O Hispanic/Latin American

Natera Managed: For Natera managed draws, our Patient Coordinators will contact the patient directly and schedule a time for a Mobile Phlebotomy Specialist to draw the sample at the patient's convenience. The sample collection kit, along with a pre-filled order form, will be shipped to the patient prior to their schedule draw.

Clinic Managed: For clinic managed draws, you are indicating that the patient's blood sample will be collected and sent by your clinic to Natera. A sample collection kit, along with a pre-filled order form, will be shipped directly to the patient to bring into the clinic, unless otherwise indicated.

SAMPLE REQUIREMENTS										
Submission Checklist: 1) S	igned order form	2) Pathology Report 3)	Most recent pro	gress/clini	ical note	4) Copy of in	surance ca	rd		
Sample Type Initial Signatera order +/- Altera			Signatera subsequent orders		Altera only		Empower (include additional Empower-labeled EDTA tube)			
Tumor Tissue w/Pathology Report						\checkmark				
EDTA Whole Blood (6mL	K2 or K3)	\checkmark				\checkmark		\checkmark		
2x Streck Plasma (10mL	Tiger Top)	\checkmark	\checkmark	\checkmark						
8. EMPOWER INFORMATION	۷*									
PATIENT COMPLETE CANCER F	ISTORY (include all	cancers and age of dx)	FAMILY HISTO	FAMILY HISTORY OF CANCER No known family history Limited family structure: Adopted or less than two 1st/2nd degree relatives living past age 45 years old Check this box if any below relatives are willing to be tested Relationship Maternal or Paternal O O						
O No personal history of cancer		<u> </u>	No known fam	nilv history						
O Patient has had genetic testing for	hereditary cancer (If ye	s, please attach the report)	-	, ,	ted or less that	n two 1st/2nd deare	e relatives livin	n past age 45 vears old		
Cancer/Tumor Age at Dx										
O Breast O Invasive Ductal O DCIS O Invasive Lobular O Triple negative (ER-, PR-, HER2-) O High-Risk HER2-** O Metastatic			Relationship	Maternal	or Paternal	Cancer site(s)	Age at Dx	Relative Deceased		
			_	0	0			0		
			-	0	0			0		
O Prostate O Metastatic O Intraductal/Cribriform O Pancreatic			_	0	0			0		
O Pancreatic				0	0			0		
O Colon/Rectal				0	0			0		
O Stomach				0	0			0		
O Other cancer(s): Type			Additional information							
Additional information				madon						
O Colon Polyps: Number of polyps										
If tumor screening was performed, select all that apply:			Known Familial Mutation: Gene: Variant:							
O MSI high? If yes, cancer type tested			Relationship Report available? O Yes (please attach) O No							
O Mismatch Repair (MMR) proteins a			Relationship		Repor		es (please atta	icn) () No		
** See NCCN.org for the definition of hi	igh-risk disease		_							
Race or ethnicity			For the full list of genes in each Empower test, visit							
O African American/Black O Native Hawaiian or other Pacific Islander			https://www.na					1997 74 24 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		
O American Indian or Alaska Native O South Asian O Ashkenazi Jewish O Southeast Asian			If you're looking					1000日11日		
O East Asian O White (Non-Hispanic)			model or the fa	amily testin	g program,	please see the	e Empower			

O Other SIGNATERA MRD & RECURRENCE MONITORING RECOMMENDED CADENCE DRAW SCHEDULE



MRD & Recurrence monitoring cadence requires the date of curative intent surgery. This cadence is available for all solid tumor histologies, and ctDNA assessment may begin BEFORE surgery, to help evaluate the effectiveness of neoadjuvant therapy and/or surgical intervention.

only test requisition or order online at oncology.natera.com

MRD & Recurrence Monitoring Recommended Cadence order directs Natera to:

When date of surgery is known (either previous or upcoming surgery date), Natera to arrange pre-surgical blood draws every 1. 4 weeks and post-surgical blood draws that approximate the schedule illustrated above.

2. If no surgery date is provided, patient will be defaulted to a 3 month schedule.

Note: Schedules may be adjusted at any time by the ordering provider, via email to OncologyCE@natera.com or by calling 650.489.9050. Recurring orders expire 12 months from date of signature

PATIENT ACKNOWLEDGMENT (READ AND SIGN THE FRONT OF THIS PAGE)

I have been informed of and understand the details of the test ordered herein for me by my/my child's health care provider, including the risks, benefits, and alternatives, and have consented to testing. I understand that the test results may inform me of a medical condition that may require medical follow-up. I also understand that a negative result does not rule out the possibility of such medical condition. I authorize Natera or other provider to share the information on this form and my/my child's test results with my/my child's insurer/health plan ("plan") on my/my child's behalf, with all benefits of my/my child's plan made payable directly to Natera or other provider. I understand that I am responsible for (a) costs not paid by my/my child's plan directly to Natera for tests ordered, including, without limitation, any copayments, deductibles, or amounts deemed 'patient responsibility' and (b) any amounts paid to me by my/my child's plan. This testing will not be covered by my/my child's plan if it is outside of the plan's coverage guidelines or deemed not medically necessary – (e.g. where prior authorization is required but not obtained) and I will be responsible for the cost of such testing. I assign to Natera the right to appeal on my/my child's behalf negative coverage decisions made by my/my child's plan and to assert all rights and claims reserved to me/my child as the beneficiary thereof. The information obtained from my/my child's tests may be used in scientific research, publications or presentations, but my/my child's specific identity will not be revealed. Natera may contact my/my child's healthcare provider to obtain more information regarding clinical correlation and confirmatory testing. My/my child's leftover samples may be de-identified, including those specimens obtained from other institutions with my consent, and used for research and development. I and my heirs will not receive payments, benefits, or rights to any resulting products or discoveries. If I do not want my/my child's samples used for research and development purposes, I will send a request in writing to Natera Sample Retention Department at the address on page 1 within 60 days after test results have been issued and my/my child's samples will be destroyed.